Mr. Hamutal Yitzhak reports

ELSE NUTRITION COMMENDS TRUMP ADMINISTRATION'S EXPANDED COMMITMENT TO BOLSTERING INFANT FORMULAS REGULATION IN FY2027

Else Nutrition Holdings Inc. has commended recent actions by the Trump Administration and the United States Food and Drug Administration (FDA) that signal increasing support for innovation and modernization within the infant formula market.

The president's budget request for fiscal year 2027 reinforces funding for infant formula modernization through the FDA's Human Foods Program, including a proposed increase of approximately $108.5-million compared with the FY2026 (fiscal 2026) enacted level. This requested increase, which was announced in early April, 2026, identifies infant formula regulation as a key investment area within this program, reflecting growing institutional prioritization.

Else believes this increased funding will expand FDA resources -- including dedicated infant formula personnel, expertise and research capabilities -- to help advance modernization efforts such as finalizing protein efficiency ratio (PER) guidance and clinical validation pathways, while enabling broader investments to strengthen the nation's infant formula supply. This intention coincides with the FY26 congressional appropriations directive report language, which encourages the FDA to implement and modernize guidance for plant-based, non-soy, non-dairy infant formulas; an area where Else is uniquely positioned as a pioneer.

Further supporting this momentum, infant formula has also been included among the FDA Human Foods Program's priority deliverables for 2026, demonstrating increased regulatory attention and potential pathway clarity for next-generation formulations. In addition, the FDA recently indicated that updated regulatory guidance on protein efficiency ratios (PER) is expected to be finalized in 2026. While final guidance has not yet been released, the agency's decision to revisit PER standards represents an encouraging step toward enabling broader innovation and modernization across the category, particularly for alternative protein sources.

"We are highly encouraged by the administration's continued focus on modernizing the regulatory framework for infant formula and advancing innovation in this critical category, as part of Operation Stork Speed," said Hamutal Yitzhak, chief executive officer and co-founder of Else Nutrition. "These developments reflect a growing recognition of the need for more diverse, high-quality nutritional options, including plant-based alternatives. As a company dedicated to redefining infant and children's nutrition, we believe these efforts will help create a more supportive environment for innovation and ultimately expand access to safe, nutritious choices for families."

Else believes that the evolving regulatory landscape, including initiatives such as Operation Stork Speed and increased FDA prioritization, has the potential to unlock new opportunities across the infant nutrition market. The company continues to monitor these developments closely and remains engaged in supporting regulatory progress that aligns with its mission to deliver clean, sustainable and nutritionally complete products.

Else expects to provide further updates as these regulatory initiatives continue to evolve.

About Else Nutrition Holdings Inc.

Else Nutrition Holdings is a food and nutrition company in the international expansion stage focused on developing innovative, clean, and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy formula is a clean-ingredient alternative to dairy-based formulas. Since launching its plant-based Complete Nutrition for Toddlers, made of whole foods, almonds, buckwheat and tapioca, the brand has received thousands of powerful testimonials and reviews from parents, gained national retailer support and achieved rapid sales growth.

We seek Safe Harbor.